A carregar...
Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases
[(223)Ra]RaCl(2) is the first alpha-particle emitting radiopharmaceutical to be used for castration-resistant prostate cancer patients with bone metastases because of its excellent therapeutic effects. [(223)Ra]RaCl(2) is excreted via the intestine into feces, and some is absorbed from the intestine...
Na minha lista:
| Publicado no: | Sci Rep |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7368038/ https://ncbi.nlm.nih.gov/pubmed/32681007 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-68846-x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|